DRXGF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 17 cases where DRXGF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 42 cases where DRXGF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on December 09, 2024. You may want to consider a long position or call options on DRXGF as a result. In of 38 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DRXGF just turned positive on December 12, 2024. Looking at past instances where DRXGF's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
DRXGF moved below its 50-day moving average on November 13, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DRXGF crossed bearishly below the 50-day moving average on November 22, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for DRXGF entered a downward trend on December 18, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.480) is normal, around the industry mean (1.840). P/E Ratio (13.680) is within average values for comparable stocks, (101.961). DRXGF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.971). Dividend Yield (0.032) settles around the average of (0.052) among similar stocks. P/S Ratio (0.306) is also within normal values, averaging (23.914).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DRXGF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry AlternativePowerGeneration
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BMCIX | 28.33 | N/A | N/A |
BlackRock High Equity Income Instl | |||
MADSX | 26.04 | N/A | N/A |
Morgan Stanley Inst Advantage R6 | |||
MDOAX | 10.46 | N/A | N/A |
Morgan Stanley Developing Opportunity A | |||
FTMCX | 24.58 | N/A | N/A |
First Trust Multi-Strategy Cl C | |||
TQAIX | 43.86 | -1.76 | -3.86% |
T. Rowe Price Integrated US Sm Gr Eq I |
A.I.dvisor tells us that DRXGF and DRXGY have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DRXGF and DRXGY's prices will move in lockstep.
Ticker / NAME | Correlation To DRXGF | 1D Price Change % | ||
---|---|---|---|---|
DRXGF | 100% | +0.04% | ||
DRXGY - DRXGF | 20% Poorly correlated | -0.41% | ||
FNEC - DRXGF | 17% Poorly correlated | N/A | ||
FOJCF - DRXGF | 4% Poorly correlated | N/A | ||
EDRVY - DRXGF | 4% Poorly correlated | N/A | ||
FOJCY - DRXGF | 3% Poorly correlated | -6.55% | ||
More |